KalVista Pharmaceuticals Inc (NASDAQ:KALV) Stock Rises 7.4% on Strong EKTERLY Launch Despite Q1 Earnings Miss KalVista stock rises 7.4% on strong EKTERLY launch, despite Q1 revenue miss and wider EPS loss. Early HAE treatment adoption exceeds expectations.
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous or subcutaneous administration.
KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment The FDA signed off on KalVista Pharmaceuticals' emergency treatment for swelling attacks associated with a rare disease.
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease KalVista's Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US.
How KalVista Pharma Is Taking On A Rare But Deadly Disease The company is working on the first new on-demand treatment for hereditary angioedema in 11 years.
KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024 KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the fourth quarter of 2024.
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
